Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
Tiziana Life Sciences (Nasdaq: TLSA) announced plans to investigate intranasal foralumab as a potential treatment for Long COVID, a condition affecting over 9 million Americans and costing the U.S. healthcare system approximately $2.6 trillion. The company emphasizes foralumab's role in deactivating activated microglia, critical in Long COVID's pathogenesis. Tiziana aims to enter a Phase 2a clinical trial pending FDA approval, using PET scans to assess the medication's effectiveness in reducing activated microglia after three months of use. The company believes that foralumab could represent a novel treatment for this debilitating condition, potentially benefiting a large patient population and addressing a significant unmet medical need.
- Plans to investigate foralumab for Long COVID treatment, tapping into a large market of over 9 million affected patients.
- Foralumab's role in deactivating activated microglia may offer a novel therapeutic pathway.
- Anticipation of entering Phase 2a clinical trial contingent upon FDA feedback.
- None.
- Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated
$2.6 trillion - The role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana’s first-in-class intranasal foralumab dampens activated microglia
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it plans to investigate intranasal foralumab for the treatment of Long COVID. The work is supported by foralumab’s well-established role in de-activating microglia cells, a key component in the pathogenesis of this disease.
“We anticipate entering into a Phase 2a placebo-controlled clinical trial upon successful feedback from the FDA”, commented Matthew W. Davis, M.D., RPh, Chief Medical Officer of Tiziana. “I am excited to test intranasal foralumab in this medically important condition. The use of PET Scans will allow us to determine if intranasal foralumab will decrease activated microglia in patients with Long COVID after 3 months of administration. After refining our clinical protocols, we need to discuss this approach with the FDA and plan to file an IND in 4Q 2023.”
“Long COVID constitutes an unmet need in society. The estimated over 9 million people in the U.S. with Long COVID will cost the healthcare system a projected
Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, stated, “The role of activated microglia is well-established in the pathogenesis of Long COVID.2,3,4,5,6,7,8 Our research using intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (SPMS), patients with COVID-19 and in healthy volunteers showed induction of a tolerogenic immune response by stimulating T regulatory cells while dampening CD3+ T effector function. In essence, intranasal foralumab modulates activated microglia while returning effector T cells to a naïve state.9 If this finding is replicated in patients with Long COVID, I believe that foralumab could represent a novel treatment for this devasting condition.”
About Foralumab
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.9
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com
1 https://jamanetwork.com/journals/jama-health-forum/fullarticle/2792505
2 Neuron. 2022 Nov 2; 110(21): 3484–3496.
3 Oxford Open Immunology, Volume 3, Issue 1, 2022, iqac007
4 N Engl J Med 2022; 387:1813-1815
5 Neuron 110, November 2, 2022:3484-3496
6 Front. Cell. Neurosci., 15 June 2021;Sec. Non-Neuronal Cells: Volume 15
7 Molecular Psychiatry (2022) 27:3939 – 3950
8 Boldrini M, Canoll PD, Klein RS. How COVID-19 Affects the Brain. JAMA Psychiatry. 2021;78(6):682–683. doi:10.1001/jamapsychiatry.2021.0500
9 https://www.pnas.org/doi/10.1073/pnas.2220272120
FAQ
What is Tiziana Life Sciences' latest initiative regarding Long COVID?
How many people in the U.S. are affected by Long COVID?
What is the estimated cost of Long COVID to the U.S. healthcare system?
When does Tiziana plan to start its Phase 2a clinical trial for foralumab?
What is the role of activated microglia in Long COVID?
